

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Boz 1450 Alexandria, Vignia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOÇKET NO.	CONFIRMATION NO.
09/744,799	04/03/2001	Paulus Jacobus Antonius Sondermeijer	1/98404 US	4801
31846	7590 08/12/2003			•
INTERVET INC 405 STATE STREET PO BOX 318			EXAM	INER
		·	SCHEINER, LAURIE A	
MILLSBORG		·	A DETARTED TO THE OWNER OF THE OWNER OF THE OWNER OWNE	
			ARTUNIT	PAPER NUMBER
		. '	1648	
	•		DATE MAILED: 08/12/2003	

Please find below and/or attached an Office communication concerning this application or proceeding.

Enclosed are the copies of the last Office Action, remailed, due to an incorrect address.

THE PERIOD FOR RESPONSE OF (one) MONTHS SET IN SAID OFFICE ACTION IS RESTARTED TO BEGIN WITH THE DATE OF THIS LETTER.

Carolyn F. Thomas,

Legal Instrument Examiner, Art Unit 1648



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR -	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/744,799	04/03/2001	Paulus Jacobus Antonius Sondermeijer	I/98404 US	4801	
75	90 06/30/2003				
William M Bla	ackstone		EXAMINER		
Akzo Nobel 1300 Piccard Di	rive Suite 206		FOLEY, SI	Y, SHANON A	
10001100					
Rockville, MD 20850-4373			ART UNIT	PAPER NUMBER	
		1648			
		•	DATE MARKED: 06/30/2003		
			Parish of octions		
		Remaile d'08/12/03			

Please find below and/or attached an Office communication concerning this application or proceeding.

, 		Application No.	Applicant(s)				
		09/744,799	SONDERMEIJER ET AL.				
	Office Action Summary	Examiner	Art Unit				
		Shanon Foley	1648				
	The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).							
Status 1)⊠	Responsive to communication(s) filed on <u>03 A</u>	pril 2001	_				
2a)□	· · · · · · · · · · · · · · · · · · ·	is action is non-final.					
3)□	Since this application is in condition for allowa		rosecution as to the merits is				
,	closed in accordance with the practice under <i>l</i> on of Claims						
4)🖂	Claim(s) 1-15 is/are pending in the application		•				
	4a) Of the above claim(s) is/are withdraw	vn from consideration.					
5) Claim(s) is/are allowed.							
6)[Claim(s) is/are rejected.						
7)	Claim(s) is/are objected to.						
8)⊠	Claim(s) 1-15 are subject to restriction and/or e	election requirement.					
Application	on Papers						
9)[] 1	The specification is objected to by the Examiner	•					
10)[] 7	The drawing(s) filed on is/are: a)□ accep	ted or b)☐ objected to by the Exa	miner.				
_	Applicant may not request that any objection to the						
11)[]] 1	The proposed drawing correction filed on		oved by the Examiner.				
If approved, corrected drawings are required in reply to this Office action.							
12) The oath or declaration is objected to by the Examiner.							
Priority under 35 U.S.C. §§ 119 and 120							
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).							
a) All b) Some * c) None of:							
	1. Certified copies of the priority documents	s have been received.					
	Certified copies of the priority documents	s have been received in Applicati	on No				
Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)), * See the attached detailed Office action for a list of the certified copies not received.							
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).							
a) The translation of the foreign language provisional application has been received. 15) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.							
Attachment(s)							
2) Notice	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Informal I	(PTO-413) Paper No(s) Patent Application (PTO-152)				

Application/Control Number: 09/744,799

Art Unit: 1648

DETAILED ACTION

Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-6, 11 and 12, drawn to an EHV mutant comprising a mutation in the endogenous promoter region of an essential gene, a vaccine comprising the mutant and a process of preparing the mutant.

Group II, claim(s) 7-10, drawn to a nucleic acid sequence encoding an endogenous promoter region of an immediate early gene from EHV.

Group III, claim(s) 13-15, drawn to a method of attenuating EHV.

The inventions listed as Groups I-III do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

The special technical feature defining group I is drawn to an equine herpesvirus comprising a mutation in the endogenous promoter region of an essential gene. This group also comprises the first method of using this virus as a vaccine and a first method of making the mutant virus. Any subsequent method of making or using the first product or any subsequent product that does not share the special technical feature with group I lacks unity of invention with the first group.

The special technical feature of group II is a second product, drawn to a nucleic acid encoding an endogenous promoter of EHV. This group does not share the special technical feature with group I because the nucleic acid does not comprise the structural components or functional capabilities inherent within the mutant EHV of group I.

The special technical feature of group III is drawn to a second method of making the first product of group I. This invention lacks unity of invention with the first group because the first group comprises a first method of making the product and any subsequent method of making lacks unity of invention with the first group.

Application/Control Number: 09/744,799

Art Unit: 1648

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Shanon Foley whose telephone number is (703) 308-3983. The examiner can normally be reached on M-F 9:00-5:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, James Housel can be reached on (703) 308-4027. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 308-4242 for regular communications and (703) 308-4426 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

June 27, 2003